Atlas Trials

Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer

Clinical trial NCT07419880 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07419880
Sponsor
Fudan University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Triple -Negative Breast Cancer
Start date
2026-01-30
Primary completion
2027-01-30
Enrollment
46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.